Uptake and release of glucose by the human kidney. Postabsorptive rates and responses to epinephrine
- PMID: 7593645
- PMCID: PMC185914
- DOI: 10.1172/JCI118314
Uptake and release of glucose by the human kidney. Postabsorptive rates and responses to epinephrine
Abstract
Despite ample evidence that the kidney can both produce and use appreciable amounts of glucose, the human kidney is generally regarded as playing a minor role in glucose homeostasis. This view is based on measurements of arteriorenal vein glucose concentrations indicating little or no net release of glucose. However, inferences from net balance measurements do not take into consideration the simultaneous release and uptake of glucose by the kidney. Therefore, to assess the contribution of release and uptake of glucose by the human kidney to overall entry and removal of plasma glucose, we used a combination of balance and isotope techniques to measure renal glucose net balance, fractional extraction, uptake and release as well as overall plasma glucose appearance and disposal in 10 normal volunteers under basal postabsorptive conditions and during a 3-h epinephrine infusion. In the basal postabsorptive state, there was small but significant net output of glucose by the kidney (66 +/- 22 mumol.min-1, P = 0.016). However, since renal glucose fractional extraction averaged 2.9 +/- 0.3%, there was considerable renal glucose uptake (2.3 +/- 0.2 mumol.kg-1.min-1) which accounted for 20.2 +/- 1.7% of systemic glucose disposal (11.4 +/- 0.5 mumol.kg-1.min-1). Renal glucose release (3.2 +/- 0.2 mumol.kg-1.min-1) accounted for 27.8 +/- 2.1% of systemic glucose appearance (11.4 +/- 0.5 mumol.kg-1.min-1). Epinephrine infusion, which increased plasma epinephrine to levels observed during hypoglycemia (3722 +/- 453 pmol/liter) increased renal glucose release nearly twofold (5.2 +/- 0.5 vs 2.8 +/- 0.1 mol.kg-1.min-1, P = 0.01) so that at the end of the infusion, renal glucose release accounted for 40.3 +/- 5.5% of systemic glucose appearance and essentially all of the increase in systemic glucose appearance. These observations suggest an important role for the human kidney in glucose homeostasis.
Similar articles
-
Kidney: its impact on glucose homeostasis and hormonal regulation.Diabetes Res Clin Pract. 2011 Aug;93 Suppl 1:S66-72. doi: 10.1016/S0168-8227(11)70016-X. Diabetes Res Clin Pract. 2011. PMID: 21864754 Review.
-
Relative importance of liver, kidney, and substrates in epinephrine-induced increased gluconeogenesis in humans.Am J Physiol Endocrinol Metab. 2003 Oct;285(4):E819-26. doi: 10.1152/ajpendo.00145.2003. Am J Physiol Endocrinol Metab. 2003. PMID: 12959936 Clinical Trial.
-
Renal substrate exchange and gluconeogenesis in normal postabsorptive humans.Am J Physiol Endocrinol Metab. 2002 Feb;282(2):E428-34. doi: 10.1152/ajpendo.00116.2001. Am J Physiol Endocrinol Metab. 2002. PMID: 11788376
-
Human kidney free fatty acid and glucose uptake: evidence for a renal glucose-fatty acid cycle.Am J Physiol. 1997 Sep;273(3 Pt 1):E650-4. doi: 10.1152/ajpendo.1997.273.3.E650. Am J Physiol. 1997. PMID: 9316458
-
Renal glucose production and utilization: new aspects in humans.Diabetologia. 1997 Jul;40(7):749-57. doi: 10.1007/s001250050745. Diabetologia. 1997. PMID: 9243094 Review.
Cited by
-
Effect of Dapagliflozin on Renal and Hepatic Glucose Kinetics in T2D and NGT Subjects.Diabetes. 2024 Jun 1;73(6):896-902. doi: 10.2337/db23-0457. Diabetes. 2024. PMID: 38512770 Clinical Trial.
-
Energy metabolic reprogramming regulates programmed cell death of renal tubular epithelial cells and might serve as a new therapeutic target for acute kidney injury.Front Cell Dev Biol. 2023 Nov 20;11:1276217. doi: 10.3389/fcell.2023.1276217. eCollection 2023. Front Cell Dev Biol. 2023. PMID: 38054182 Free PMC article. Review.
-
Liver or kidney: Who has the oar in the gluconeogenesis boat and when?World J Diabetes. 2023 Jul 15;14(7):1049-1056. doi: 10.4239/wjd.v14.i7.1049. World J Diabetes. 2023. PMID: 37547592 Free PMC article. Review.
-
Gluconeogenesis in the kidney: in health and in chronic kidney disease.Clin Kidney J. 2023 Mar 14;16(8):1249-1257. doi: 10.1093/ckj/sfad046. eCollection 2023 Aug. Clin Kidney J. 2023. PMID: 37529654 Free PMC article. Review.
-
Therapeutic Targeting of SGLT2: A New Era in the Treatment of Diabetes and Diabetic Kidney Disease.Front Endocrinol (Lausanne). 2021 Nov 1;12:749010. doi: 10.3389/fendo.2021.749010. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34790170 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous